Novel RNA-targeting antisense therapy is shown to reduce lipoprotein(a) levels in 286 patients with existing atherosclerotic disease by upwards of 80% in a phase 2 clinical trial.
This is a preview of subscription content, log in via an institution to check access.
References
Tsimikas, S. et al. J. Am. Coll. Cardiol. 71, 177–192 (2018).
Tsimikas, S. et al. N. Engl. J. Med. 382, 244–255 (2020).
Paré, G. et al. Circulation 139, 1472–1482 (2019).
Clarke, R. et al. N. Engl. J. Med. 361, 2518–2528 (2009).
Burgess, S. et al. JAMA Cardiol. 3, 619–627 (2018).
Thanassoulis, G. et al. N. Engl. J. Med. 368, 503–512 (2013).
de Oliveira Sá, M. P. B. et al. Curr. Atheroscler. Rep. 22, 2 (2020).
Boffa, M. B. & Koschinsky, M. L. Nat. Rev. Cardiol. 16, 305–318 (2019).
Willeit, P. et al. Lancet 392, 1311–1320 (2018).
Wilson, D. P. et al. J. Clin. Lipidol. 13, 374–392 (2019).
Varvel, S., McConnell, J. P. & Tsimikas, S. Arterioscler. Thromb. Vasc. Biol. 36, 2239–2245 (2016).
O’Donoghue, M. L. et al. Circulation 139, 1483–1492 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. J. R. serves on the Scientific Advisory Board for Alnylam, which makes small interfering RNA therapeutics, and for Novartis, which has licensed AKCEA-APO(a)-LRx.
Rights and permissions
About this article
Cite this article
Bajaj, A., Rader, D.J. Antisense oligonucleotides for atherosclerotic disease. Nat Med 26, 471–472 (2020). https://doi.org/10.1038/s41591-020-0835-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0835-2
- Springer Nature America, Inc.